XFOR

3.0001.35%
RT

Renato T. Skerlj

Founder

Dr. Renato T. Skerlj, Ph.D., has been President, Chief Executive Officer and Director of Expansion Therapeutics, Inc. since October 05, 2020. Dr. Skerlj served as Member of Clinical & Scientific Advisory Board of Vasomune Inc. until 2024. He serves as a Member of Scientific Advisory Board at Escient Pharmaceuticals, Inc. He was a Co-Founder of Noliva Therapeutics (January 2013 - January 2020). He served as the Chief Scientific Officer at X4 Pharmaceuticals Inc. since June 2020 until October 02, 2020 and served as Senior Vice President of Research and Development since September 2019 until June 2020. He serves as Vice President of Drug Discovery and Preclinical Development at Lysosomal Therapeutics Inc (December 2017 - September 2019). Dr. Skerlj is the Founder of X4 Pharmaceuticals Inc. since July 2014. He has pharmaceutical experience in drug discovery and development resulting in two marketed drugs: Invanz and Mozobil. He served as the Head of Small Molecule Discovery at Genzyme (July 2011 - May 2012). He served as a Vice President of Chemistry of AnorMED Inc.(April 2002 - May 2007). He joined AnorMED Inc. in 1998. From 1995 to 1998, he served as Senior Research Chemist at Merck & Co., Inc. He served as a Senior Scientist of Johnson Matthey's biomedical research group until 1995. He has been a Member of Scientific & Clinical Advisory Board at MetaStat, Inc. since August 3, 2017. He served as a Member of Scientific Advisory Board at X4 Pharmaceuticals Inc until October 02, 2020. Dr. Skerlj holds a Ph.D. in Synthetic Organic Chemistry from the University of British Columbia in 1988 and did Post-Doctoral Research at the University of Oxford (U.K.) in 1990 and Ohio State University in 1991 and holds BSc (Hons), Chemistry from University of Otago in 1982.

Positions